Congratulations to Marina Baretti, MD of Johns Hopkins University! On May 30, she was recognized with a Career Development Award (CDA) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This highly prestigious award provides three years of research funding to clinical investigators to establish an independent clinical cancer research program.

These awards are funded by Conquer Cancer®, the ASCO Foundation. To be considered for this Career Development Award, an investigator must be conducting clinical or translational research involving patients. U.S. and international applicants active in all areas of cancer are considered. While Dr. Baretti has been involved in treating and researching a range of liver, pancreatic and biliary tree cancers, she was recognized for this award largely due to her activities in fibrolamellar – in particular her leadership in both the peptide vaccine and glutamine antagonist clinical trials now underway at Johns Hopkins.

FCF is thrilled that the impact of Dr. Baretti’s clinical research in fibrolamellar is being broadly recognized by the medical community. We are also pleased that her outstanding efforts are focusing attention and research funding on this devastating disease.